• Home
  • Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.

Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.

Author List
Raffit Hassan, Marcus O. Butler, David Yoonsuk Oh, Roisin Eilish O'Cearbhaill, Lauren MacMullen, Erin Jeter, Udayan Guha, Viera P. Muzithras, Kevin Zikaras, Melissa Lynne Johnson, Janos Laszlo Tanyi, Azam Ghafoor, Robert Tighe, Munisha Smalley, Alfonso Quintas-Cardama, David S. Hong
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/420600843
Publication Year
2023
Publication Title
Raffit Hassan, Marcus O. Butler, David Yoonsuk Oh, Roisin Eilish O'Cearbhaill, Lauren MacMullen, Erin Jeter, Udayan Guha, Viera P. Muzithras, Kevin Zikaras, Melissa Lynne Johnson, Janos Laszlo Tanyi, Azam Ghafoor, Robert Tighe, Munisha Smalley, Alfonso Quintas-Cardama, David S. Hong. Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):8537-8537.